Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Operating Leases of $40.2 million for Q2 2026, up 26.42% year-over-year from $31.8 million in Q2 2025, and down 1.79% on a QoQ basis from $40.9 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $40.2 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $40.2 million, up 26.42% year-over-year; the trailing twelve-month figure through Jun 2026 was $40.2 million (up 26.42% YoY), and the FY2025 annual result was $41.0 million, up 19.57% from the prior year.
- Operating Leases slipped to $40.2 million in Q2 2026, from $40.9 million in the prior quarter.
- Over five years, Operating Leases peaked at $46.0 million in Q1 2022 and troughed at $31.8 million in Q2 2025.
- A 5-year average of $40.5 million and a median of $41.8 million in 2023 frame the typical range for Operating Leases.
- The widest annual swing landed in 2025, when Operating Leases decreased 23.32%; it then advanced 26.62% in 2026.
- A 5-year view of Operating Leases shows it stood at $42.8 million in 2022, then declined by 2.95% to $41.5 million in 2023, then slipped by 17.47% to $34.3 million in 2024, then climbed by 19.57% to $41.0 million in 2025, then declined by 1.97% to $40.2 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $40.2 million in Q2 2026, $40.9 million in Q1 2026, and $41.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.17 Mn |
| Mar 31, 2026 | 40.90 Mn |
| Dec 31, 2025 | 40.98 Mn |
| Sep 30, 2025 | 31.42 Mn |
| Jun 30, 2025 | 24.38 Mn |
| Mar 31, 2025 | 26.37 Mn |
| Dec 31, 2024 | 34.27 Mn |
| Sep 30, 2024 | 38.15 Mn |
| Jun 30, 2024 | 30.29 Mn |
| Mar 31, 2024 | 32.99 Mn |
| Dec 31, 2023 | 41.53 Mn |
| Sep 30, 2023 | 33.84 Mn |
| Jun 30, 2023 | 42.20 Mn |
| Mar 31, 2023 | 44.09 Mn |
| Dec 31, 2022 | 36.00 Mn |
| Sep 30, 2022 | 36.03 Mn |
| Jun 30, 2022 | 44.12 Mn |
| Mar 31, 2022 | 46.03 Mn |
| Dec 31, 2021 | 41.30 Mn |
| Sep 30, 2021 | 43.17 Mn |